ICE regimen: Difference between revisions

	WikiDoc Resources for ICE regimen
Articles
Most recent articles on ICE regimen Most cited articles on ICE regimen Review articles on ICE regimen Articles on ICE regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on ICE regimen Images of ICE regimen Photos of ICE regimen Podcasts & MP3s on ICE regimen Videos on ICE regimen
Evidence Based Medicine
Cochrane Collaboration on ICE regimen Bandolier on ICE regimen TRIP on ICE regimen
Clinical Trials
Ongoing Trials on ICE regimen at Clinical Trials.gov Trial results on ICE regimen Clinical Trials on ICE regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on ICE regimen NICE Guidance on ICE regimen NHS PRODIGY Guidance FDA on ICE regimen CDC on ICE regimen
Books
Books on ICE regimen
News
ICE regimen in the news Be alerted to news on ICE regimen News trends on ICE regimen
Commentary
Blogs on ICE regimen
Definitions
Definitions of ICE regimen
Patient Resources / Community
Patient resources on ICE regimen Discussion groups on ICE regimen Patient Handouts on ICE regimen Directions to Hospitals Treating ICE regimen Risk calculators and risk factors for ICE regimen
Healthcare Provider Resources
Symptoms of ICE regimen Causes & Risk Factors for ICE regimen Diagnostic studies for ICE regimen Treatment of ICE regimen
Continuing Medical Education (CME)
CME Programs on ICE regimen
International
ICE regimen en Espanol ICE regimen en Francais
Business
ICE regimen in the Marketplace Patents on ICE regimen
Experimental / Informatics
List of terms related to ICE regimen

VisualWikitext

Latest revision as of 12:58, 27 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords:Carboplatin/Etoposide/Ifosfamide; CBDCA/IFF/VP-16; ICE; ICE Regimen; ICE regimen; Ifosfamide-Carboplatin-Etoposide Regimen

Overview

ICE regimen refers to a chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of non-Hodgkin and hodgkin lymphomas.^[1]^[2]

Regimen

IIfosfamide

CCarboplatin

EEtoposide

Indications

Relapsed and refractory non-Hodgkin and Hodgkin lymphomas.^[1]

References

↑ ^1.0 ^1.1 Xia W, Ma CK, Reid C, Bai L, Wong K, Kerridge I; et al. (2014). "Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation". J Clin Apher. 29 (6): 322–30. doi:10.1002/jca.21340. PMID 24944079.
↑ "NCI Thesaurus".

[pmid24944079-1] 1.0 ^1.1 Xia W, Ma CK, Reid C, Bai L, Wong K, Kerridge I; et al. (2014). "Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation". J Clin Apher. 29 (6): 322–30. doi:10.1002/jca.21340. PMID 24944079.

[2] "NCI Thesaurus".

[1]

[2]

@@ Line 10: / Line 10: @@
 ==Regimen==
 {{chemo|I|Ifosfamide}}
 {{chemo|C|Carboplatin}}
 {{chemo|E|Etoposide}}
 ==Indications==
 *Relapsed and refractory [[Non-Hodgkin lymphoma|non-Hodgkin]] and [[Hodgkin's lymphoma|Hodgkin lymphomas]].<ref name="pmid24944079">{{cite journal| author=Xia W, Ma CK, Reid C, Bai L, Wong K, Kerridge I et al.| title=Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation. | journal=J Clin Apher | year= 2014 | volume= 29 | issue= 6 | pages= 322-30 | pmid=24944079 | doi=10.1002/jca.21340 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24944079 }} </ref>